EXEL Is A Buyout Candidate In The Making
By Lowenthal Capital Partners
At this juncture, an EXEL buyout could be hinged on a number of key developments. Positive OS data for Cometriq certainly tops the list. Novartis and Bristol-Meyers could be potential suitors. Strong OS data for Cometriq would undermine the commercial prospects of Opdivo and Afinitor, thus offering incentives for both companies to buy EXEL at a hefty premium in order to retain market share.
It is possible that BMY may outright buy EXEL to capitalize on the success of Cometriq, as well as possible synergies between cobimetinib and vermurafenib (Zelboraf) - which I will elucidate. Aside from Cometriq, the early stage studies of cobimetinib in combination with Zelboraf in advanced solid tumors could help attract buyout interest. Zelboraf is a relatively important product of Genentech, a subsidiary ofRoche(OTCQX:RHHBY). Thus, it is possible that EXEL would attract further buyout interest from Roche if cobimetinib is shown to complement Zelboraf for the treatment of advanced solid tumors.
Thanks all $$
Anthera Pharmaceuticals,Momentum Charts to Watch
07/23/15 8:30 P.M.
Anthera Pharmaceuticals ( ANTH ) The stock popped to resistance on Monday and again on Wednesday, up 62 cents, or 6.1%, to $10.77 on no news. Volume was a solid 1.6 million. It looks like it wants to go further, and targets are $14 and then the channel top near $18.50.
Wall Street 24/7
By Chris Lange July 21, 2015 5:29 pm EDT
Exelixis announced positive top-line results from its primary analysis of METEOR, the Phase 3 pivotal trial comparing cabozantinib to everolimus in 658 patients with metastatic renal cell carcinoma (RCC). These patients have experienced disease progression following treatment with a VEGF receptor tyrosine kinaseinhibitor. Cabozantinib reduced the risk of disease progression or death by 42% compared to the everolimus.
Juno Announces FDA Acceptance of New Drug Application for JCAR017 in Relapsed/Refractory B Cell Non-Hodgkin Lymphoma
The drug works by taking the patient's own cells out, essentially training them to fight the cancer cells,then infusing them back into the patient's body. Tests showed a 91 percent remission rate in patientswith leukemia and lymphoma Less
this is the title of the news story - google it
Juno Therapeutics stock soars as FDA approves new drug for non-Hodgkin lymphomaJun 29, 2015, 7:29am PDT Updated Jun 29, 2015, 7:33am PDT
No comparison, FIT ill be higher share price than GPRO
not good sign
Recently, I asked another investor whose opinion I trust about Kirk's comments. That person warned me that Kirk is a bit of a cult hero who has a large following of investors who have an unwarranted opinion of his ability to move the markets. Indeed similar comments can be found in a Google search, and an increasing number of investors apparently have doubts about the promise of Ziopharm
5:59 P.m. EST
Deutsche Bank Reiterated Rating Buy $60.00
Old News and Already Discussed, He Had a Client Who Was A Short See CNBC VIDEO That Discussed This
thanks and good luck